Skip directly to search Skip directly to A to Z list Skip directly to navigation Skip directly to page options Skip directly to site content


Main|Search|PHGKB
Search PHGKB:

Last Posted: Oct 04, 2024
spot light Highlights

Crossing the Equity Chasm: Addressing a Second Valley of Death in Biomedical Innovation

From the article: "Recent transformative advances in health and medicine have successfully traversed the valley of death, including progress in genomics, precision medicine, innovative medicines and vaccines, gene therapy, and artificial intelligence. However, it is critical to call attention to a second, important valley of death: the failure to deliver scientific advances to populations most in need. The second valley of death is fueled by socioeconomic, environmental, political, and systemic factors; health system failures; and persistent challenges in closing the last mile in health care, resulting in significant disparities in morbidity and mortality worldwide. "

Every baby deserves access to genetic screening

From the article: "Nation-wide genetic screening, available to all newborns, could in principle also be a tool to narrow the disparities that exist in today’s healthcare systems, providing to every family information about their baby’s health, regardless of socioeconomic and geographical factors. Designing genomics-based newborn screening programs that bring benefit equitably to the population is, however, an extremely complex task, also given the costs, and there is an urgent need to generate robust evidence on the potential benefits and harms of the approach, at the population level, before it can be implemented more widely. "

Sustaining Community Engagement in Genomics Research: A Workshop

From the website: "This hybrid workshop will examine how researchers could more meaningfully engage and sustain interactions with historically underrepresented communities in research to foster their participation in genomics and precision health studies. The overarching goal of the workshop is to help improve the quality of genomics research by understanding where obstacles to sustained community involvement remain. "

Pharmacogenomics, Race, and Treatment Outcome in Pediatric Acute Myeloid Leukemia

From the abstract: " Can tailoring the intensity of induction therapy mitigate racial disparities in the outcome of pediatric patients with acute myeloid leukemia (AML)? Findings: In this comparative effectiveness analysis of 86 Black and 359 White patients with AML, Black patients exhibited a higher prevalence of low cytarabine pharmacogenomic 10–single-nucleotide variant (ACS10) scores, which were associated with an unfavorable outcome after initial treatment with low-dose cytarabine-based induction therapy. Augmentation of induction therapy was associated with improved outcome for patients with low ACS10 scores and with no disparity in outcome between Black patients and White patients."

Search Result Summary


Disclaimer: Articles listed in the Public Health Genomics and Precision Health Knowledge Base are selected by the CDC Office of Public Health Genomics to provide current awareness of the literature and news. Inclusion in the update does not necessarily represent the views of the Centers for Disease Control and Prevention nor does it imply endorsement of the article's methods or findings. CDC and DHHS assume no responsibility for the factual accuracy of the items presented. The selection, omission, or content of items does not imply any endorsement or other position taken by CDC or DHHS. Opinion, findings and conclusions expressed by the original authors of items included in the update, or persons quoted therein, are strictly their own and are in no way meant to represent the opinion or views of CDC or DHHS. References to publications, news sources, and non-CDC Websites are provided solely for informational purposes and do not imply endorsement by CDC or DHHS.

TOP